---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-029405"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:44:22.641599+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS Q2 net loss $13.3M, revenue $1.3M; cash runway into Q1 2024

## Summary
- BREXAFEMME net revenue $1.3M in Q2 2022, up 86% from $0.7M in Q1.
- Net loss $13.3M ($0.31/shr) vs net gain $1.7M ($0.06/shr) in Q2 2021.
- Cash $118.7M at June 30, 2022; projected runway into Q1 2024.
- FDA accepted sNDA for BREXAFEMME in recurrent VVC; PDUFA date Nov 30, 2022.
- Total prescriptions up 29% QoQ to ~5,141; >2,200 HCPs prescribed in Q2.

## SEC filing metadata
- accession: 0001564590-22-029405
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000156459022029405/0001564590-22-029405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000156459022029405/scyx-8k_20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-029405
- JSON: https://secwatch.observer/filing/0001564590-22-029405.json
- Plain text: https://secwatch.observer/filing/0001564590-22-029405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.